134 天前 - … the DAPA-HF trial that revealed a substantial reduction in adverse cardiovascular
outcomes with dapagliflozin in patients … of dapagliflozin on patients of rheumatic heart disease …

135 天前 - … DAPA-HF and DELIVER trials demonstrated the clinical benefits of dapagliflozin in
heart failure (HF) patients … real-world HF patients eligible for dapagliflozin and evaluates the …

139 天前 - … participant‐level data from DELIVER and DAPA‐HF, we found that the addition
of dapagliflozin to standard of care in patients with HF across the full spectrum of EF was of …

139 天前 - … is restricted to the heart failure team in the absence of … dapagliflozin added to
SoC against SoC alone in patients … practices, the dapagliflozin dose in the DAPA-HF trail was …

156 天前 - … Our imputation of all-cause mortality metrics 279 for dapagliflozin, empagliflozin, and
… trials of currently approved heart failure drugs. We predict that the trials DAPA-MI and 281 …

170 天前 - … 2 diabetes (T2D) or heart failure (HF). The trial was conducted … DAPA-MI achieved
its revised primary end point, with a … win for patients treated with dapagliflozin early post-MI? …

171 天前 - … DAPA-HF trial found a significant reduction in mortality with the use of dapagliflozin
in patients with HF … Dapagliflozin in heart failure with mildly reduced or preserved ejection …

199 天前 - … in 2020), and heart failure (the DAPA-HF study is scheduled to … cardiovascular
and renal outcomes, the major objective of the current study was to determine how dapagliflozin …

209 天前 - … the effects of dapagliflozin in patients with HF with and without sleep apnea in a
pooled analysis of 2 trials comparing dapagliflozin to placebo in HFrEF (DAPA-HF trial) and …

218 天前 - … with heart failure (HF).Despite the mechanisms leading to … HF hospitalization in
the EMPEROR-Reduced and DAPA-… dapagliflozin compared with placebo in 17 160 patients …